Live subgroup B respiratory syncytial virus vaccines that are attenuated, genetically stable, and immunogenic in rodents and nonhuman primates

Journal of Infectious Diseases

Volumn 173, Issue 4, 1996, Pages 829-839

  Crowe Jr , James E ^a,b   Bui, Phuong T ^a   Firestone, Cai Yen ^a   Connors, Mark ^a   Elkins, William R ^a   Chanock, Robert M ^a   Murphy, Brian R ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^b VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RESPIRATORY SYNCYTIAL VIRUS VACCINE;

ANIMAL CELL; ARTICLE; IMMUNOGENICITY; NONHUMAN; PRIORITY JOURNAL; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; VIRUS ATTENUATION; VIRUS GENE; VIRUS REPLICATION;

EID: 0029889634     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1093/infdis/173.4.829     Document Type: Article

References (31)

1. McIntosh KM, Chanock RM. Respiratory syncytial virus. In: Fields BN, ed. Virology. New York: Raven Press, 1990:1045-72.
2. Waris M. Pattern of respiratory syncytial virus epidemics in Finland: two-year cycles with alternating prevalence of groups A and B. J Infect Dis 1991;163:464-9.
3. Mufson MA, Belshe RB, Orvell C, Norrby E. Subgroup characteristics of respiratory syncytial virus strains recovered from children with two consecutive infections. J Clin Microbiol 1987;25:1535-9.
4. Henderson FW, Collier AM, Clyde WA Jr, Denny FW. Respiratory syncytial virus infections, reinfections, and immunity: a prospective, longitudinal study in young children. N Engl J Med 1979;300:530-4.
5. Chanock RM, Murphy BR. Past efforts to develop safe and effective RSV vaccines. In: Meigner B, Murphy B, Ogra P, eds. Animal models of respiratory syncytial virus infections. Lyon, France: Merieux Foundation, 1991:35-42.
6. Wright PF, Shinozaki T, Fleet W, Sell SH, Thompson J, Karzon DT. Evaluation of a live, attenuated respiratory syncytial virus vaccine in infants. J Pediatr 1976;88:931-6.
7. Wright PF, Belshe RB, Kim HW, Van Voris LP, Chanock RM. Administration of a highly attenuated, live respiratory syncytial virus vaccine to adults and children. Infect Immun 1982;37:397-400.
8. Kim HW, Arrobio JO, Pyles G, et al. Clinical and immunological response of infants and children to administration of low temperature adapted respiratory syncytial virus. Pediatrics 1971;48:745-55.
9. Kim HW, Canchola JG, Brandt CD, et al. Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine. Am J Epidemiol 1969;89:422-34.
10. Kapikian AZ, Mitchell RH, Chanock RM, Shvedoff RA, Stewart CE. An epidemiologic study of altered clinical reactivity to respiratory syncytial (RS) virus infection in children previously vaccinated with an inactivated RS virus vaccine. Am J Epidemiol 1969;89:405-21.
11. Crowe JE Jr, Collins PL, London WT, Chanock RM, Murphy BR. A comparison in chimpanzees of the immunogenicity and efficacy of live attenuated respiratory syncytial virus (RSV) temperature-sensitive mutant vaccines and vaccinia virus recombinants that express the surface glycoproteins of RSV. Vaccine 1993;11:1395-404.
12. Crowe JE Jr, Bui PT, London WT, et al. Satisfactorily attenuated and protective mutants derived from a partially attenuated cold passaged respiratory syncytial virus mutant by introduction of additional attenuating mutations during chemical mutagenesis. Vaccine 1994;12:691-9.
13. Crowe JE Jr, Bui PT, Davis AR, Chanock RM, Murphy BR. A further attenuated derivative of a cold-passaged temperature-sensitive mutant of human respiratory syncytial virus retains immunogenicity and protective efficacy against wild-type challenge in seronegative chimpanzees. Vaccine 1994;12:783-90.
14. Crowe JE Jr, Bui PT, Siber GR, Elkins WR, Chanock RM, Murphy BR. Cold-passaged, temperature sensitive mutants of human respiratory syncytial virus (RSV) are highly attenuated, immunogenic, and protective in seronegative chimpanzees, even when RSV antibodies are infused shortly before immunization. Vaccine 1995;13:847-55.
15. Prince GA, Jenson AB, Horswood RL, Camargo E, Chanock RM. The pathogenesis of respiratory syncytial virus infection in cotton rats. Am J Pathol 1978;93:771-92.
16. Lewis FA, Rae ML, Lehman NI, Ferris AA. A syncytial virus associated with epidemic disease of the lower respiratory tract in infants and young children. Med J Aust 1961;2:932-3.
17. Hall SL, Stokes A, Tierney EL, et al. Cold-passaged parainfluenza type 3 viruses contain ts and non-ts mutations leading to attenuation in rhesus monkeys. Virus Res 1992;22:173-84.
18. Coates HV, Ailing DW, Chanock RM. An antigenic analysis of respiratory syncytial virus isolates by a plaque reduction neutralization test. Am J Epidemiol 1966;83:299-313.
19. Cane PA, Pringle CR. Molecular epidemiology of respiratory syncytial virus: rapid identification of subgroup A lineages. J Virol Methods 1992;40:297-306.
20. Cane PA, Matthews DA, Pringle CR. Analysis of respiratory syncytial virus strain variation in successive epidemics in one city. J Clin Microbiol 1994;32:1-4.
21. Murphy BR, Sotnikov AV, Lawrence LA, Banks SM, Prince GA. Enhanced pulmonary histopathology is observed in cotton rats immunized with formalin-inactivated respiratory syncytial virus (RSV) or purified F glycoprotein and challenged with RSV 3-6 months after immunization. Vaccine 1990;8:497-502.
22. Walsh EE, Schlesinger JJ, Brandriss MW. Purification and characterization of gp90, one of the envelope glycoproteins of respiratory syncytial virus. J Gen Virol 1984;65:761-7.
23. Walsh EE, Brandriss MW, Schlesinger JJ. Purification and characterization of the respiratory syncytial virus fusion protein. J Gen Virol 1985;66:409-15.
24. Erwin J, Landon JC. Spacious biocontainment suites for chimpanzees in infectious disease research. In: Erwin J, Landon JC, eds. Chimpanzee conservation and public health: environments for the future. Rockville, MD: Diagnon/Bioqual, 1992:65-9.
25. Kakuk TJ, Soike K, Brideau RJ, et al. A human respiratory syncytial virus (RSV) primate model of enhanced pulmonary pathology induced with a formalin-inactivated RSV vaccine but not a recombinant FG subunit vaccine. J Infect Dis 1993;167:553-61.
26. Johnson PR, Olmsted RA, Prince GA, et al. Antigenic relatedness between glycoproteins of human respiratory syncytial virus subgroups A and B: evaluation of the contributions of F and G glycoproteins to immunity. J Virol 1987;61:3163-6.
27. Richman DD, Murphy DR. The association of the temperature-sensitive phenotype with viral attenuation in animals and humans: implications for the development and use of live virus vaccines. Rev Infect Dis 1979;1:413-33.
28. Pringle CR, Filipiuk AH, Robinson BS, Watt PJ, Higgins P, Tyrrell DAJ. Immunogenicity and pathogenicity of a triple temperature-sensitive modified respiratory syncytial virus in adult volunteers. Vaccine 1993;11:473-8.
29. Randolph VB, Kandis M, Stemler-Higgins P, et al. Attenuated temperature-sensitive respiratory syncytial virus mutants generated by cold-adaptation. Virus Res 1994;33:241-59.
30. Wright PF, Karzon DT. Live attenuated influenza vaccines. Prog Med Virol 1987;34:70-88.
31. Tatem JM, Weeks-Levy C, Georgiu A, et al. A mutation present in the amino terminus of Sabin 3 poliovirus VP1 protein is attenuating. J Virol 1992;66:3194-7.